NCT04762069Phase 2Active not recruiting

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Study sponsor: CNS Pharmaceuticals, Inc. · CNSP

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-04-27Estimated

Enrollment · participants252Actual

Source updated2026-04-15Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-15 · 3 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~210 participants (planned)~~

+ After

252 participants (actual)

Primary completion date changed

− Before

~~1 Feb 2026~~

+ After

27 Apr 2026

Check registry source

Study details

Conditions studied

Glioblastoma Multiforme, Adult

Treatments or interventions studied

BerubicinDrugAlso known as Berubicin Hydrochloride
LomustineDrugAlso known as Lomustine Capsules, CCNU, CeeNU, Gleostine

Primary outcomes · main study measures

measure: Overall Survival; description: To assess the effect of berubicin compared with lomustine on overall survival (OS) in adult patients with GBM that has recurred or progressed after standard initial therapy; timeFrame: Through study completion an average of 4 years.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history